Oruka Therapeutics stock analysis
Oruka Therapeutics (0H79) Share Price & Analysis
0H79 Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- $6.73B
- Enterprise Value
- $5.05B
- Total Cash (Recent Filing)
- $920.28M
- Total Debt (Recent Filing)
- $2.93M
- Price to Earnings (P/E)
- ―
- Beta
- N/A
- Next Earnings
- Mar 11, 2027 (Est.)
- EPS Estimate
- -0.75
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Phase 2b Clinical Efficacy
Strong Phase 2b efficacy and favorable safety support advancing ORKA-001 toward Phase 3 and potentially differentiate it from existing psoriasis biologics. If replicated, high disease-clearance rates and infrequent dosing could strengthen adoption and create a durable commercial opportunity.
Cash Resources
A substantial cash and securities position gives Oruka the resources to continue clinical development and pursue a planned biologics license application without immediate dependence on operating revenue. This supports execution through important value-creating milestones over the next several quarters.
Low Financial Leverage
Extremely low leverage preserves financial flexibility because limited debt reduces fixed obligations and refinancing pressure. The larger equity base can support continued investment in clinical programs, although the company must ultimately convert that capital into products and future commercial returns.
Bears Say
Pre-revenue Business Model
The absence of product revenue means Oruka currently relies on capital rather than commercial cash inflows to fund operations. Until a candidate is approved and launched, financial performance will remain tied to clinical execution, regulatory progress, and access to external funding.
Widening Net Losses
Rapidly widening losses show that operating investment is increasing faster than any developing revenue base, leaving near-term earnings visibility weak. Continued clinical and overhead spending may be appropriate for the company’s stage, but it raises the capital required before a product can generate returns.
Substantial Cash Burn
Persistent and worsening negative free cash flow indicates that Oruka is consuming substantial cash while its pipeline remains pre-commercial. Unless development produces a revenue inflection or strategic funding event, ongoing burn increases the likelihood of future financing and potential shareholder dilution.
Oruka Therapeutics News
ORKA-002 Trial Progress: What Oruka’s New HS Study Means for Investors
Oruka Therapeutics, Inc. ($ORKA) announced an update on their ongoing clinical study. The study A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-002
0H79 FAQ
What is Oruka Therapeutics’s market cap?
When is Oruka Therapeutics’s upcoming earnings report date?
How were Oruka Therapeutics’s earnings last quarter?
Is Oruka Therapeutics overvalued?
Does Oruka Therapeutics pay dividends?
What is Oruka Therapeutics’s EPS estimate?
What happened to Oruka Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Oruka Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Oruka Therapeutics Stock Smart Score
Company Description
Oruka Therapeutics
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Lawrence Otto Klein
- Employees
- 68
- Website
- www.orukatx.com
- Address
- 855 Oak Grove Avenue, Menlo Park, CA, 94025, US














